PMC:7546122 / 13999-14298 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T70","span":{"begin":62,"end":68},"obj":"Body_part"},{"id":"T71","span":{"begin":166,"end":172},"obj":"Body_part"},{"id":"T72","span":{"begin":243,"end":249},"obj":"Body_part"}],"attributes":[{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"With increasing numbers of human infections, including in the plasma donor community, it is interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations and, after the several months production cycle time between plasma donation and IVIG lot release, also in IVIG lots."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T71","span":{"begin":33,"end":43},"obj":"Disease"},{"id":"T72","span":{"begin":152,"end":160},"obj":"Disease"}],"attributes":[{"id":"A71","pred":"mondo_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"With increasing numbers of human infections, including in the plasma donor community, it is interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations and, after the several months production cycle time between plasma donation and IVIG lot release, also in IVIG lots."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T139","span":{"begin":27,"end":32},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T140","span":{"begin":62,"end":68},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T141","span":{"begin":166,"end":172},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T142","span":{"begin":243,"end":249},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"With increasing numbers of human infections, including in the plasma donor community, it is interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations and, after the several months production cycle time between plasma donation and IVIG lot release, also in IVIG lots."}

{"project":"LitCovid-sentences","denotations":[{"id":"T99","span":{"begin":0,"end":299},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"With increasing numbers of human infections, including in the plasma donor community, it is interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations and, after the several months production cycle time between plasma donation and IVIG lot release, also in IVIG lots."}

{"project":"LitCovid-PubTator","denotations":[{"id":"272","span":{"begin":27,"end":32},"obj":"Species"},{"id":"273","span":{"begin":152,"end":162},"obj":"Species"},{"id":"280","span":{"begin":33,"end":43},"obj":"Disease"}],"attributes":[{"id":"A272","pred":"tao:has_database_id","subj":"272","obj":"Tax:9606"},{"id":"A273","pred":"tao:has_database_id","subj":"273","obj":"Tax:2697049"},{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"With increasing numbers of human infections, including in the plasma donor community, it is interesting to follow the development of antibodies against SARS-CoV-2 in plasma donations and, after the several months production cycle time between plasma donation and IVIG lot release, also in IVIG lots."}